Brain Natriuretic Peptide (BNP) Usefulness In Elderly Dyspneic Patients (BED)
The purpose of this study is to test the usefulness of measuring plasma brain natriuretic peptide (BNP) for diagnosis and prognosis in very elderly dyspneic patients.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Usefulness of Measuring Plasma Brain Natriuretic Peptide for Diagnosis and Prognosis in Very Elderly Patients.|
- Plasma BNP levels at T0 to test the optimal values of measuring plasma BNP for diagnosis of HF in patients older than 80 years. [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- Plasma BNP levels at 3 times (T0, T48, Tend) to test the usefulness of measuring plasma BNP : 1.at T0 : in diagnosing HF using a 2-threshold up-and down-approach [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
- 2.at T48 : in diagnosing and prognosing HF using a 2nd assay after 48 hours of treatment [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
- 3.at Tend : in prognosing HF using a 3rd assay after the acute phase (composite criteria) [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
Biospecimen Retention: Samples Without DNA
Blood sample for brain natriuretic peptide measurement
|Study Start Date:||June 2007|
|Study Completion Date:||February 2012|
|Primary Completion Date:||August 2011 (Final data collection date for primary outcome measure)|
Prospective study : cohort of consecutive patients recruited over 2 years
Measurement of BNP concentration is approved for use in the diagnosis of heart failure (HF) in elderly patients below 80 years of age. The value of plasma BNP assays as diagnostic tools has not been determined in very elderly populations because the plasma BNP increases with age. This large, multicenter, prospective, observational, study in 300 participants is aimed to prospectively test the usefulness of measuring plasma BNP for diagnosis of HF in dyspneic patients aged 80 and older.